Viewing nowMemantine 20 mg Tablet (Memantine Hydrochloride)
Memantine Hydrochloride 20mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

MFDS item code 202500399 · Approved 2025.02.25 · Insurance code 693903980
Treatment of moderate to severe Alzheimer's disease
This medication is used for the treatment of moderate to severe Alzheimer's disease.
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer's dementia, and only if a caregiver is available to regularly check that the patient is taking the medication. Diagnosis should be made according to currently accepted guidelines. The clinical benefit of this drug and the patient's tolerability of treatment should be reassessed regularly. This drug is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. 1. Adults Dose titration: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, reach the maintenance dose by increasing the dose by 5mg per week over the first 3 weeks as follows. Week 1 (Days 1–7): Administer 5mg daily for 7 days. Week 2 (Days 8–14): Administer 10mg daily for 7 days. Week 3 (Days 15–21): Administer 15mg daily for 7 days. From Week 4 onward, administer 20mg daily. Maintenance dose: The recommended maintenance dose is 20mg daily. 2. Older adults Based on clinical data, the recommended dose for patients aged 65 years and older is 20mg daily. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg daily according to the standard dose-titration regimen. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this drug.
This medication should not be used in patients with a known allergy to its components. It should not be administered to patients with severely impaired liver function or severely decreased kidney function. Patients with a history of epilepsy or seizures, as well as those at high risk of seizures, should use this medication with caution. Avoid concomitant use with drugs that have similar effects, such as Amantadine, Ketamine, and Dextromethorphan, as adverse effects may be exacerbated. Patients with conditions or diseases that may alter urinary acidity should be carefully monitored when taking this medication. Caution is needed as the safety of this medication has not been sufficiently confirmed in recent myocardial infarction, heart failure, or uncontrolled hypertension patients. This medication may cause side effects such as dizziness, headache, constipation, drowsiness, and hypertension; if these symptoms occur, consult a healthcare provider. This medication may interact with other drugs, so inform your healthcare provider of any medicines you are taking. Caution is especially needed when taken with medications affecting blood clotting or those acting on the nervous system. Women who are pregnant or may become pregnant should consult a doctor before taking this medication, and breastfeeding should be stopped if this medication is being used. It is recommended that this medication is not used in children or adolescents under 18 years of age as its safety and efficacy have not been established. In case of overdose, symptoms such as confusion, drowsiness, dizziness, and vomiting may occur; immediate medical attention should be sought. This medication may affect concentration and response times, so special care should be taken when driving or operating machinery. Keep out of reach of children, and avoid transferring the medication to another container.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius. This will help preserve the medication's efficacy and safety over time.
Pink oval film-coated tablet
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 20mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.